Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children

Br J Haematol. 2013 May;161(3):402-5. doi: 10.1111/bjh.12238. Epub 2013 Feb 6.

Abstract

Elevated foetal haemoglobin (HbF) levels are protective against some manifestations of sickle cell anaemia but the impact on retinopathy is unknown. We report on 123 children with HbSS, 10.6% of whom developed retinopathy. Independent of hydroxycarbamide, children with a HbF <15% had 7.1-fold (95% confidence interval, 1.5-33.6) higher odds of developing retinopathy. In children treated with hydroxycarbamide, those with retinopathy had lower HbF levels compared to children without retinopathy (9% vs. 16%; P = 0.005). We report a protective benefit of elevated HbF regarding retinopathy, and our data suggests induction of HbF with hydroxycarbamide may prevent retinopathy in children.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / drug therapy
  • Antisickling Agents / therapeutic use*
  • Child
  • Drug Evaluation
  • Female
  • Fetal Hemoglobin / analysis*
  • Fetal Hemoglobin / biosynthesis
  • Fetal Hemoglobin / genetics
  • Follow-Up Studies
  • Gene Expression Regulation / drug effects
  • Humans
  • Hydroxyurea / therapeutic use*
  • Incidence
  • Male
  • Retinal Diseases / blood
  • Retinal Diseases / epidemiology
  • Retinal Diseases / etiology
  • Retinal Diseases / prevention & control*
  • Retrospective Studies
  • Risk
  • Vitreoretinopathy, Proliferative / blood
  • Vitreoretinopathy, Proliferative / epidemiology
  • Vitreoretinopathy, Proliferative / etiology
  • Vitreoretinopathy, Proliferative / prevention & control

Substances

  • Antisickling Agents
  • Fetal Hemoglobin
  • Hydroxyurea